Sugi Predict

Sugi Predict / Compounds / SCHEMBL660982

SCHEMBL660982

SCHEMBL660982

O=c1[nH]ccc2ccoc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 4/20 0.42
▸ MAOA P21397 3/20 0.39
▸ MAOB P27338 2/20 0.39
▸ JAK2 O60674 1/20 0.37
▸ RPS6KA3 P51812 1/20 0.37
▸ MELK Q14680 1/20 0.37
▸ STK24 Q9Y6E0 1/20 0.37
▸ AURKA O14965 1/20 0.35
▸ AURKB Q96GD4 1/20 0.35
▸ INCENP Q9NQS7 1/20 0.35
▸ CHEK1 O14757 1/20 0.34
▸ HTR2A P28223 1/20 0.34
▸ HTR2C P28335 1/20 0.34
▸ HTR2B P41595 1/20 0.34
▸ MAPT P10636 1/20 0.33
▸ NFKB1 P19838 1/20 0.32
▸ CYP1A2 P05177 2/20 0.32
▸ CYP3A4 P08684 2/20 0.32
▸ CYP2D6 P10635 1/20 0.32
▸ CYP2A6 P11509 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21305080 0.74 BRD4 (0.41) PARP1MAOAMAOBMAPK1GRM5
SCHEMBL4426880 0.74 TNF (0.39) MAOAMAOBHTR2AHTR2CHTR2B
SCHEMBL4419988 0.67 MAOA (0.46) MAOAMAOBHTR2AHTR2CHTR2B
SCHEMBL29591293 0.67 MAOA (0.46) MAOAMAOBHTR2AHTR2CHTR2B
SCHEMBL8821629 0.67 MAOA (0.41) PARP1MAOAMAOBHTR2AHTR2C
SCHEMBL126092 0.65 PARP1 (0.42) PARP1MAOAMAOBHTR2AHTR2C
SCHEMBL1980989 0.64 MAOA (0.39) MAOAMAOBHTR2AHTR2CHTR2B
SCHEMBL15068024 0.64 PARP1 (0.50) PARP1MAOAMAOBJAK2RPS6KA3
SCHEMBL2114197 0.64 CCR8 (0.45) MAOAMAOBALDH1A1KDM4ELMNA
SCHEMBL1550253 0.63 PARP1 (0.46) PARP1RPS6KA3CHEK1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138956-A1 NOVEL COMPOUNDS AND USES THEREOF RECURSION PHARMACEUTICALS INC (US) 2026-05-21 — — US disclosed
EP-4739307-A2 TARGETED EPIGENETIC THERAPIES FOR DISORDERS OF PROGRANULIN DEFICIENCY The General Hospital Corporation (US) 2026-05-13 — — EP disclosed
US-12545700-B2 Excitonic quantum computing via aggregate-aggregate coupling BOISE STATE UNIVERSITY (US) 2026-02-10 — — US disclosed
US-12479998-B2 Dyes in dye aggregate systems—engineering J, K, and dye packing BOISE STATE UNIVERSITY (US) 2025-11-25 — — US disclosed
EP-4638438-A1 ALPHA4 BETA7 INTEGRIN ANTAGONISTS AND USES THEREOF Xinthera, Inc. (US) 2025-10-29 — — EP disclosed
EP-4134364-B1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RES INC (US) 2025-07-30 — — EP disclosed
US-12292668-B2 Molecular aggregate for optically-pumped nonreciprocal exciton devices BOISE STATE UNIVERSITY (US) 2025-05-06 — — US disclosed
US-20250092054-A1 FUSED PYRIDINES FOR CONTROLLING INVERTEBRATE PESTS FMC CORPORATION 2025-03-20 — — US disclosed
WO-2025010291-A2 TARGETED EPIGENETIC THERAPIES FOR DISORDERS OF PROGRANULIN DEFICIENCY THE GENERAL HOSPITAL CORPORATION (US) 2025-01-09 — — WO disclosed
US-12173027-B2 Excitonic quantum computing mediated by chromophore-embedded 1-, 2-, and 3-dimensional DNA scaffolds BOISE STATE UNIVERSITY (US) 2024-12-24 — — US disclosed
US-7799775-B2 such as 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-ylpiperazin-1-yl)propylthio]-3H-thieno[2,3-d]pyrimidin-4-one, having serotonin receptor modulatory activity, used for treating irritable bowel syndrome ASKA PHARMACEUTICAL CO., LTD. (JP) 2010-09-21 — — US disclosed
US-7799775-B2 such as 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-ylpiperazin-1-yl)propylthio]-3H-thieno[2,3-d]pyrimidin-4-one, having serotonin receptor modulatory activity, used for treating irritable bowel syndrome ASKA PHARMACEUTICAL CO., LTD. (JP) 2010-09-21 — — US disclosed
US-20070197551-A1 Pyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-23 — — US disclosed
US-20070197551-A1 Pyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-23 — — US disclosed
US-20070197551-A1 Pyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-23 — — US disclosed
EP-1724267-A1 PYRIMIDINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2006-11-22 — — EP disclosed
US-20040122223-A1 Non-natural nucleotides and dinucleotides CELLTECH R & D LIMITED (GB) 2004-06-24 — — US disclosed
EP-1368366-A1 NON-NATURAL NUCLEOTIDES AND DINUCLEOTIDES Celltech R & D Limited (GB) 2003-12-10 — — EP disclosed
WO-2002062816-A1 NON-NATURAL NUCLEOTIDES AND DINUCLEOTIDES CELLTECH R & D LIMITED (GB) 2002-08-15 — — WO disclosed
US-4808595-A REDUCTION OF PRESSURE DUE TO GLAUCOMA MERCK & CO., INC. (US) 1989-02-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197551-A1 Pyrimidine derivatives HTR3B, HTR3A, HTR1A PARP1 1036/4885MAOA 423/4885MAOB 315/4885
US-20260138956-A1 NOVEL COMPOUNDS AND USES THEREOF SLC10A1, NR3C2, CYP2C8 PARP1 3969/4885MAOA 1064/4885MAOB 1355/4885
US-20250092054-A1 FUSED PYRIDINES FOR CONTROLLING INVERTEBRATE PESTS PRF1, ACHE, C5 PARP1 2920/4885MAOA 880/4885MAOB 1345/4885
US-20040122223-A1 Non-natural nucleotides and dinucleotides P2RY1, P2RY11, P2RY13 PARP1 543/4885MAOA 3666/4885MAOB 3006/4885
US-12545700-B2 Excitonic quantum computing via aggregate-aggregate coupling ELAVL1, ELAVL3, NCAPH PARP1 416/4885MAOA 4194/4885MAOB 4402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.